Department of Pharmacy, Uppsala University, Husargatan 3, Box 580, SE-75123, Uppsala, Sweden.
The Swedish Drug Delivery Center, Department of Pharmacy, Uppsala University, Uppsala, Sweden.
Pharm Res. 2020 May 20;37(6):99. doi: 10.1007/s11095-020-02833-9.
To evaluate the performance of artificial membranes in in vitro lipolysis-permeation assays useful for absorption studies of drugs loaded in lipid-based formulations (LBFs).
Polycarbonate as well as PVDF filters were treated with hexadecane, or lecithin in n-dodecane solution (LiDo) to form artificial membranes. They were thereafter used as absorption membranes separating two compartments mimicking the luminal and serosal side of the intestine in vitro. Membranes were subjected to dispersions of an LBF that had been digested by porcine pancreatin and spiked with the membrane integrity marker Lucifer Yellow (LY). Three fenofibrate-loaded LBFs were used to explore the in vivo relevance of the assay.
Of the explored artificial membranes, only LiDo applied to PVDF was compatible with lipolysis by porcine pancreatin. Formulation ranking based on mass transfer in the LiDo model exposed was the same as drug release in single-compartment lipolysis. Ranking based on observed apparent permeability coefficients of fenofibrate with different LBFs were the same as those obtained in a cell-based model.
The LiDo membrane was able to withstand lipolysis for a sufficient assay period. However, the assay with porcine pancreatin as digestive agent did not predict the in vivo ranking of the assayed formulations better than existing methods. Comparison with a Caco-2 based assay method nonetheless indicates that the in vitro in vivo relationship of this cell-free model could be improved with alternative digestive agents.
评估人工膜在体外脂肪分解渗透测定中的性能,这些测定对于研究载药脂质体制剂(LBFs)的吸收有用。
聚碳酸酯和聚偏二氟乙烯过滤器用十六烷或大豆卵磷脂在正十二烷溶液(LiDo)中处理,以形成人工膜。然后,它们被用作吸收膜,将两个模拟肠道腔侧和浆膜侧的隔室隔开。将已被猪胰蛋白酶消化并加入膜完整性标记物 Lucifer Yellow(LY)的 LBF 分散体施加到膜上。使用三种载有非诺贝特的 LBF 来探索该测定在体内的相关性。
在所探索的人工膜中,只有 LiDo 应用于聚偏二氟乙烯与猪胰蛋白酶的脂肪分解相容。基于 LiDo 模型中脂肪转移的配方排序与单一隔室脂肪分解中的药物释放相同。基于不同 LBF 的非诺贝特观察到的表观渗透系数的排序与在基于细胞的模型中获得的排序相同。
LiDo 膜能够承受足够长的测定时间的脂肪分解。然而,用猪胰蛋白酶作为消化剂的测定并不能比现有方法更好地预测所测定配方的体内排序。与 Caco-2 为基础的测定方法相比,然而,表明这个无细胞模型的体外-体内相关性可以通过替代消化剂来改善。